Abstract: A combination therapy for cardiovascular diseases, in particular essential hypertension, pulmonary hypertension and/or congestive heart failure, involving administering a synergistic combination of at least one inhibitor of neutral endopeptidase, at least one inhibitor of the endogenous endothelin producing system, and at least one AT1 receptor antagonist.
Type:
Application
Filed:
June 20, 2005
Publication date:
December 29, 2005
Applicant:
SOLVAY PHARMACEUTICALS GmbH
Inventors:
Dieter Ziegler, Klaus Witte, Matthias Straub, Yvan Fischer, Dirk Thormaehlen, Dagmar Hoeltje
Abstract: A combination therapy for the inhibition and/or treatment of sexual dysfunction and/or cardiovascular diseases in humans and other mammals, by administering a synergistic combination of at least one inhibitor of neutral endopeptidase, at least one inhibitor of the endogenous endothelin producing system, and at least one inhibitor of phosphodiesterase 5.
Type:
Application
Filed:
May 12, 2005
Publication date:
December 1, 2005
Applicant:
Solvay Pharmaceuticals GmbH
Inventors:
Dieter Ziegler, Klaus Witte, Matthias Straub, Michael Weske, Dagmar Hoeltje
Abstract: The present invention relates to the novel medicinal use of dually acting compounds capable of inhibiting neutral endopeptidase (=NEP) and human soluble endopeptidase (=hSEP) in the prophylaxis and/or treatment of sexual dysfunction in mammals and humans.
Type:
Application
Filed:
May 12, 2005
Publication date:
December 1, 2005
Applicant:
Solvay Pharmaceuticals GmbH
Inventors:
Dieter Ziegler, Klaus Witte, Matthias Straub, Michael Weske
Abstract: The present invention relates to the use of known and novel N-sulfamoyl-N?-arylpiperazines corresponding to Formula I and their physiologically compatible acid addition salts for the treatment or inhibition of obesity and related conditions.
Type:
Application
Filed:
May 17, 2005
Publication date:
November 24, 2005
Applicant:
Solvay Pharmaceuticals GmbH
Inventors:
Jochen Antel, Michael Firnges, Peter-Colin Gregory, Uwe Reinecker, Uwe Schoen, Harald Waldeck, Michael Wurl, Dania Reiche
Abstract: A method of using 3,7-diazabicyclo[3,3,1]nonane compounds, preferably of 9,9-alkylene-3,7-diazabicyclo[3,3,1]nonane compounds, and most preferably to the use of tedisamil, and the physiologically acceptable acid addition salts and/or solvates thereof, in the form of a liquid pharmaceutical preparation for the treatment and/or inhibition of arrhythmic events in human patients, preferably in conversion of recent onset of atrial fibrillation or flutter to normal sinus rhythm in humans, as well as related methods and pharmaceutical products or packages.
Type:
Application
Filed:
July 13, 2005
Publication date:
November 24, 2005
Applicant:
Solvay Pharmaceuticals GmbH
Inventors:
Matthias Straub, Johannes Wilhelmus Catharine Maria Jansen, Michiel de Vries, Claus Steinborn, Werner Cautreels
Abstract: Orally administrable pharmaceutical compositions of lipase-containing products, particularly pancreatin and pancreatin-containing products, or of enzyme products which contain at least one lipase of non-animal, especially microbial origin, which improve the lipolytic activity and particularly result in stabilization of the lipase in the acidic pH range. These oral pharmaceutical compositions contain a system which includes at least one surfactant and one co-surfactant and optionally a lipophilic phase, and are self-emulsifiable on contact with a hydrophilic and a lipophilic phase. The compositions according to the invention are suitable for treating or inhibiting maldigestion, especially maldigestion due to chronic exocrine pancreatic insufficiency, in mammals and humans.
Abstract: A method of treating or inhibiting depression in a patient with cardiovascular disease, especially a patient suffering from coronary artery or vascular disease, the method including administering, preferably orally, to the patient a therapeutically effective amount of an essential fatty acid composition comprising preferably more than 25% by weight of eicosapentanoic acid ethyl ester (EPA), of docosahexaenoic acid ethyl ester (DHA), or of a mixture of eicosapentanoic acid ethyl ester (EPA) and docosahexaenoic acid ethyl ester (DHA), especially a mixture of EPA and DHA in an EPA/DHA ratio in the range from about 0.9 to about 1.5 at a dosage of from about 0.7 g to about 6 g per day.
Abstract: Abstract of the Disclosure The present invention relates to a novel medical use of 4,5-dihydro-1H-pyrazole compounds which are potent antagonists of the cannabis CB1-receptor. Said compounds are particularly suitable in the manufacture of medicaments for the treatment and/or prophylaxis of CB1 receptor related diseases in juvenile patients and/or for the treatment and/or prophylaxis of drug induced obesity in juvenile as well as in adolescent patients. The compounds have the general formula (I) wherein the group Bb represents sulfonyl or carbonyl, and the substituents R, R1, R2 and R3, and the group Aa are defined as shown in the description.
Abstract: A method of treating or inhibiting non-digestive tract derived abdominal disorders associated with pain, in particular interstitial cystitis, chronic pelvic pain syndrome and/or abdominal pain associated with endometriosis, in a patient in need thereof, by administering to the patient a pharmaceutically effective amount of a 5-HT3 receptor antagonist, in particular cilansetron, or a pharmacologically compatible derivative thereof, such as a salt and/or a solvates.
Abstract: A method for the discovery of compounds suitable for the treatment and/or prophylaxis of obesity, in which the ability of the test compounds to inhibit de novo lipogenesis in mammals and/or man is determined. The use of compounds which are capable of inhibiting de novo lipogenesis in mammals, and which are substantially free of effects directed towards the CNS, for the preparation of pharmaceutical compositions for the treatment and/or prophylaxis of obesity, as well as for the treatment and/or inhibition of obesity, are also described.
Type:
Grant
Filed:
July 18, 2001
Date of Patent:
September 20, 2005
Assignee:
Solvay Pharmaceuticals GmbH
Inventors:
Johannes Hebebrand, Jochen Antel, Ulf Preuschoff, Samuel David, Holger Sann, Michael Weske
Abstract: Substituted ?-lactones (oxetanones) corresponding to the formula I, wherein R1, R2 and n have the meanings given in the specification, and pharmaceutical compositions which contain these compounds and have a pancreatic lipase-inhibiting action, as well as a process for the preparation of the compounds of Formula I and intermediate products of this process.
Type:
Application
Filed:
February 22, 2005
Publication date:
September 8, 2005
Applicant:
Solvay Pharmaceuticals GmbH
Inventors:
Jochen Antel, Sabine Eyting, Peter Gregory, Harald Waldeck, Michael Wurl, Maike Wolff
Abstract: 3,15-substituted estrone compounds which act as inhibitors of 17?-hydroxysteroid dehydrogenase type I (17?-HSD1), salts thereof, pharmaceutical preparations containing such compounds, processes for preparing such compounds, and therapeutic uses of such compounds, particularly in the treatment or inhibition of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of 17?-hydroxysteroid dehydrogenase type I enzymes and/or requiring the lowering of the endogenous 17?-estradiol concentration, as well as the general use of selective 17?-hydroxysteroid dehydrogenase type 1 inhibitors which possess in addition no or only pure antagonistic binding affinities to the estrogen receptor for the treatment or inhibition of benign gynecological disorders, particularly endometriosis.
Type:
Application
Filed:
November 9, 2004
Publication date:
September 1, 2005
Applicant:
Solvay Pharmaceuticals GmbH
Inventors:
Josef Messinger, Heinrich-Hubert Thole, Bettina Husen, Bartholomeus Van Steen, Gyula Schneider, Johannes Bernardus Hulshof, Pasi Koskimies, Nina Johansson, Jerzy Adamski
Abstract: Novel and known trifluoroacetyl-substituted phenyl, phenol and benzoyl compounds for the treatment and/or inhibition of obesity and of concomitant and/or secondary diseases involved therewith, in particular metabolic syndrome and cardiovascular diseases. Novel trifluoroacetyl-substituted phenyl, phenol and benzoyl compounds, pharmaceutical preparations containing them and processes for the preparation of these compounds. Also compounds acting as inhibitors of lipase, in particular pancreatic lipase.
Type:
Grant
Filed:
January 16, 2004
Date of Patent:
August 16, 2005
Assignee:
Solvay Pharmaceutical GmbH
Inventors:
Jochen Antel, Harald Waldeck, Andreas Potthoff, Sabine Irmer, Peter-Colin Gregory
Abstract: Thiophenepyrimidinone compounds and their use in therapy, especially for use in the treatment and/or prevention of a steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring inhibition of 17?-hydroxysteroid dehydrogenase enzymes.
Inventors:
Leena Hirvelae, Nina Johansson, Pasi Koskimies, Olli Pentikaeinen, Tommi Nyroenen, Tiina Salminen, Mark Johnson, Pekka Lehtovuori, Pauli Saarenketo, Bartholomeus Van Steen, Heinrich-Hubert Thole, Mikko Unkila, Josef Messinger, Johanna Kiviniemi, Lila Pirkkala, Bettina Husen
Abstract: Selectively BRS-3-agonistic compounds of formula I wherein A1, A2, A3, R1, R2, R3, Ar1, Ar2, Ar3, m and n have the meanings given in the description, and also pharmaceutical compositions containing these compounds and a process for the preparation of compounds of Formula I are described.
Type:
Application
Filed:
December 3, 2004
Publication date:
August 4, 2005
Applicant:
Solvay Pharmaceuticals GmbH
Inventors:
Dirk Weber, Horst Kessler, Claudia Berger, Jochen Antel, Timo Heinrich
Abstract: The use of selective imidazoline receptor agonists, such as moxonidine, rilmenidine, LNP-509, S-23515, PMS-812, PMS-847 and BU-98008, and their physiologically compatible acid addition salts in pharmaceutical preparations for the treatment and/or inhibition of functional disorders and/or diseases in larger mammals or humans which require inhibition or reduction of the activity of proteins which regulate the intracellular pH value and which belong to the superfamily of bicarbonate transporters, in particular the treatment or inhibition of clinical conditions of bones which are caused by an undesirable amount of bone resorption, such as osteoporosis; of diseases of the gastrointestinal tract, such as gastric ulcers; and of neuronal and/or neuropsychiatric diseases associated with a pathologically altered (especially increased) neuronal activity, such as depression, Alzheimer's disease, eating disorders and schizophrenia.
Type:
Application
Filed:
December 17, 2004
Publication date:
July 28, 2005
Applicant:
Solvay Pharmaceuticals GmbH
Inventors:
Heinz Rupp, Bernd Eisele, Dieter Ziegler, Bodo Jaeger, Bernhard Maisch
Abstract: Compounds corresponding to formula I: in which R1, R2, R3, R4, R5 and R6 have the meanings given in the description; a process for the preparation of these compounds; intermediate products used to prepare such compounds, and pharmaceutical compositions containing such compounds.
Type:
Application
Filed:
October 12, 2004
Publication date:
July 7, 2005
Applicant:
Solvay Pharmaceuticals GmbH
Inventors:
David Sykes, Brian Moloney, Lester Marrison, Dieter Ziegler, Michael Mlinaric, Christiane Boecker, Reinhard Brueckner, Michael Weske, Klaus Witte, Yvan Fischer
Abstract: Parmaceutical compositions comprising selective imidazoline receptor agonists combined with angiotensin II receptor blockers, particularly, pharmaceutical compositions comprising Moxonidine and Eprosartan mesylate, as well as the use of such compositions for the treatment of hypertension, especially in hypertensive patients suffering from type II diabetes or susceptible to developing type II diabetes.
Abstract: Treatment and/or inhibition of renal dysfunction, disease or disorder in larger mammals, and particularly in humans, especially in human patients suffering from diabetes, using benzazepine-N-acetic acid derivatives which contain an oxo-group in the ?-position to the nitrogen atom and are substituted in position 3 by a 1-(carboxyalkyl)cyclopentylcarbonylamino radical, and/or salts or biolabile esters or physiologically acceptable solvates thereof, and production of pharmaceutical compositions and products suitable for treatment and/or inhibition of renal dysfunction, disease or disorder, particularly in diabetic patients, but also in patients with syndrome X or in patients with a renal dysfunction, disease and/or disorder, which patients are additionally hypertensive, obese, hyperglycemic and/or subject to a metabolic disorder.
Type:
Application
Filed:
November 16, 2004
Publication date:
June 23, 2005
Applicant:
Solvay Pharmaceuticals GmbH
Inventors:
Dirk Thormaehlen, Berthold Hocher, Harald Waldeck
Abstract: Compounds having neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity corresponding to the formula 1, wherein the substituents R1, R2, R3 and R4 have the meanings given in the description and also pharmaceutical compositions containing these compounds, in particular pharmaceutical compositions suitable for treating or inhibiting cardiovascular diseases, sexual dysfunction and/or adverse conditions associated with apoptosis.
Type:
Application
Filed:
September 24, 2004
Publication date:
June 2, 2005
Applicant:
Solvay Pharmaceuticals GmbH
Inventors:
Dagmar Hoeltje, Yvan Fischer, Dieter Ziegler, Michael Weske, Katrin Michaelis, Yasmin Karimi-Nejad, Josef Messinger, Axel Pahl, Constanze Hoefer, Hrissanthi Ikonomidou, Lechoslaw Turski